Psychiatry Infrastructure Lags Psychedelic Momentum, With Gus Alva, MD

Psychiatry currently lacks the infrastructure and trained workforce required to safely deliver 

 at scale, despite accelerating policy and research momentum, according to Gus Alva, MD, psychiatrist and medical director of ATP Clinical Research. Speaking in the context of recent federal efforts to expand access and research, Alva emphasized that adaptability exists within the field, but implementation capacity remains limited.

He noted that patients with risk factors such as bipolar disorder, psychosis vulnerability, or cardiovascular disease may require careful screening, including detailed psychiatric and family histories and trauma-informed assessments. Current trial protocols, he explained, rely on highly trained therapists, often requiring > 100 hours of specialized preparation.

“The reality is that we right now don't have a therapist pool in the US that would be able to actually fill in this particular slot,” Alva said. “Bear in mind also that these sessions require about 6 to 8 hours of dosing with facilitators, as well as medical backup…physical space, and integration sessions that are done before and after.”

He highlighted integration expertise as central to potential benefit, noting that clinicians must help patients process experiences during a period of heightened neuroplasticity. He also emphasized the importance of safety protocols, including contingency planning for difficult psychological responses, emergent suicidality, psychotic symptoms, or cardiovascular events.

Alva’s comments follow the April 18 executive order signed by President Donald J. Trump directing federal agencies to accelerate research and regulatory pathways for investigational psychedelic therapies.1,2 Alva cautioned that infrastructure development must keep pace with policy changes.

“What this executive order basically brought to the surface is that the way or the conduit for actually exploring psychedelics is going to become a little bit easier,” he said.

According to Alva, the executive order may help address persistent treatment gaps in major depressive disorder (MDD) or PTSD, where many patients do not achieve remission with current therapies. However, he raised concerns about applying Right to Try pathways to Schedule I psychedelics without sufficient safeguards. Although he characterized expanded clinical trial activity as necessary, he emphasized that premature adoption without adequate training, monitoring, and infrastructure could introduce risks.

“[A] training pipeline would certainly be one of the requisites that we'd be looking at,” Alva said.

Relevant disclosures for Alva include Teva Pharmaceuticals, Otsuka America Pharmaceuticals, AbbVie Inc., Axsome Therapeutics, Janssen Pharmaceuticals, and more.

O’Neil G. Accelerating Medical Treatments for Serious Mental Illness. The White House. Published on April 18, 2026. Accessed April 20, 2026. 

https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/

Kotkiewicz J. Fact Sheet: President Donald J. Trump is Accelerating Medical Treatments for Serious Mental Illness. The White House. Published April 18, 2026. 

https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/

Videos

Alva discusses infrastructure gaps, training demands, and unmet psychiatric need amid accelerated policy momentum for psychedelic therapies.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

PTSD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

The emergence of targeted biologic therapies in severe 

 has fundamentally altered the treatment paradigm for a disease once managed almost exclusively through inhaled corticosteroids and bronchodilators. Across a growing portfolio of approved agents — omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, tezepelumab, and most recently depemokimab — the identification of type 2 (T2) inflammation via blood eosinophil count and fractional exhaled nitric oxide (FeNO) has enabled a precision medicine approach that was unimaginable a decade ago. Real-world registry data from the International Severe Asthma Registry (ISAR), now encompassing nearly 35,000 patients across 28 countries, indicate that approximately 30–50% of biologic-treated patients achieve clinical remission when defined by elimination of exacerbations, OCS discontinuation, normalized lung function, and symptom control — a target outcome once considered unattainable in severe disease.¹ In chronic obstructive pulmonary disease (COPD), the landscape has evolved more recently but is generating comparable enthusiasm: dupilumab and mepolizumab have both received regulatory approval as add-on therapies for patients with eosinophilic COPD who continue to exacerbate despite triple inhaled therapy, based on the BOREAS/NOTUS and MATINEE trial programs respectively.²

 convened a virtual clinical forum in April 2026 moderated by Antonio Anzueto, MD, emeritus professor at the University of Texas San Antonio and a member of the GOLD Guidelines Committee — bringing a clinical trialist's perspective to both guideline context and emerging evidence. The panel comprised seven pulmonary and critical care physicians based across Texas, in San Antonio, Houston, Dallas, and Plano, representing a mix of academic medical centers, county hospital systems, and private practice settings. The geographic and practice-setting diversity of the panel grounded the discussion in real-world challenges of biologic access and patient management in a state with high asthma burden and significant populations affected by COPD driven by biofuel and occupational exposures.

The forum convened at a moment when several concurrent developments are reshaping clinical practice in both diseases. The December 2025 FDA approval of depemokimab — the first twice-yearly biologic for severe eosinophilic asthma — has expanded the IL-5 class while introducing new questions about dosing interval management and real-world adherence.

 Publication of mucus plug scoring data from the VESTIGE trial in the 

American Journal of Respiratory and Critical Care Medicine

 has introduced CT-based mucus plug quantification as a potential third biomarker for asthma biologic response, one the moderator argued will be routinely incorporated into practice within the coming years.

 Foundational data from the COPDGene cohort demonstrating that airway-occluding mucus plugs are independently associated with excess all-cause mortality and exacerbations in COPD have further elevated this imaging phenotype as a therapeutic target.

 And the GOLD 2026 report has formally incorporated biologics into the COPD escalation algorithm while strengthening the recommendation for baseline CT chest in all patients with COPD.

The most substantive discussion in the asthma segment centered on biologic selection and the practical limitations clinicians face in applying biomarker-driven decision-making. Panelists confirmed broad biologic adoption, with dupilumab as the most commonly initiated agent and eosinophil count as the primary selection driver, followed by FeNO where clinic access permitted. Availability of FeNO testing varied considerably across the group — some practices had integrated it into standard spirometry workflows, while county hospital systems lacked the equipment entirely. Anzueto described a practical model for cost justification through billing code development, noting the machine typically offsets its cost within the first several days of use in high-volume asthma practices. Polling results identified biomarkers as the leading clinical selection driver, but panelists consistently noted that insurance formulary placement and prior authorization requirements often determine the actual agent prescribed, effectively overriding clinical reasoning. 

The 2019 decision by GINA and GOLD to retire the asthma-COPD overlap (ACOS) classification was cited as a concrete example of how labeling can affect access — that reclassification was partly motivated by the recognition that ACOS designation was blocking biologic eligibility for patients who fundamentally had asthma. Depemokimab's six-month dosing interval was viewed as conceptually appealing for adherence-challenged patients, but insurance non-coverage was the primary barrier at forum time, and panelists raised questions about how patients and clinicians would recognize suboptimal disease control across such an extended interval. Combination biologic therapy — an approach occasionally attempted anecdotally in very severe OCS-dependent cases — was confirmed to have no supporting clinical trial data.

The mucus plug discussion represented the most scientifically forward-looking segment of the forum. Drawing on COPDGene's standardized CT methodology and biologic trial data from VESTIGE and CASCADE, Anzueto presented mucus plug scoring as an emerging third biomarker for asthma that could eventually predict biologic response alongside eosinophils and FeNO. In VESTIGE, patients with high baseline mucus plug scores (≥4) showed disproportionate improvements in pre-bronchodilator FEV1 at weeks 4, 12, and 24 with dupilumab, while low-score patients demonstrated no meaningful lung function benefit — suggesting mucus plug burden identifies a mechanistically responsive subgroup.

 CASCADE data with tezepelumab showed a parallel pattern.

 The moderator flagged an active randomized trial of dupilumab vs. placebo in chronic bronchitis COPD with mucus plug assessment as a primary endpoint, and noted that software tools for integrating mucus scoring into routine radiology reads are already in commercial development. Panelists were largely unfamiliar with this data, and several expressed interest in how it might eventually stratify biologic candidates in moderate disease below the current exacerbation-based threshold.

“I think what we need to do is we need to have our eyes open because these are going to be an area that we're going to see a lot of activity in the near future. Stratifying the patient's severity, not only based on the biomarkers that are traditionally eosinophils, the FeNO, the oral corticosteroids, until we can identify, oh, that's a severe individual. At 1 point, we'll be able to identify those patients based on the mucus plugs,” Anzueto said.

In the COPD segment, the panel reflected a field at an earlier stage of biologic integration, with greater uncertainty about patient selection and more significant access barriers. All panelists reported routinely checking eosinophil counts in new COPD patients — some reviewing historical CBCs retrospectively — but Anzueto noted that many automated panels do not include eosinophil differentials, leaving a practical data gap particularly relevant in county and safety-net settings. Real-world experience with dupilumab in COPD was described as mixed: exacerbation reduction was the most consistent finding, while FVC improvement was less reliably replicated outside the trial setting, particularly at borderline eosinophil thresholds. 

Anzueto contextualized declining apparent effect sizes in recent mepolizumab COPD trials — noting that baseline exacerbation rates in MATINEE (~1.01/year) were substantially lower than in earlier METREX/METREO studies (~1.7/year) as a direct consequence of optimized triple therapy raising the performance floor.

 Polling revealed that payer support and reimbursement guidance was the factor panelists most wanted to improve biologic integration in COPD, followed by clearer patient selection algorithms. Anzueto closed by reinforcing GOLD 2026's strong recommendation for baseline CT in all patients diagnosed with COPD — citing data showing that 60% of one cohort had significant coronary calcifications that had gone undetected, underscoring CT's value beyond pulmonary phenotyping — and predicting that AI-driven quantification of mucus plugs, emphysema burden, and small airway disease will ultimately define the next generation of COPD biomarkers.

Larenas-Linnemann D, Rhee CK, Altraja A, et al. International Severe Asthma Registry (ISAR): 2017–2024 status and progress update. 

 2025;88(2):193-215. doi:10.4168/trd.2024.0208

Criner GJ, Celli BR, Bhatt SP, et al. Mepolizumab for COPD with exacerbations and eosinophilia. 

 2023;389(23):2127-2138. doi:10.1056/NEJMoa2303120

Jackson DJ, Wechsler ME, Menzies-Gow A, et al; SWIFT-1 and SWIFT-2 Investigators. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. 

 2024;391(24):2337-2349. doi:10.1056/NEJMoa2406673

Porsbjerg CM, Dunican EM, Lugogo NL, et al. Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial. 

 Published online October 27, 2025. doi:10.1164/rccm.202410-1894OC

Diver S, McDowell PJ, Siddiqui S, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. 

 2024;3(3):EVIDoa2300135. doi:10.1056/EVIDoa2300135

Diaz AA, Orejas JL, Grumley S, et al. Airway-occluding mucus plugs and mortality in patients with chronic obstructive pulmonary disease. 

 2023;329(21):1832-1839. doi:10.1001/jama.2023.2065

Global Initiative for Chronic Obstructive Lung Disease. 

Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report.

Articles

Targeted biologics have transformed severe asthma management by enabling biomarker-driven selection using blood eosinophils and FeNO, with registry data showing 30–50% remission in biologic-treated patients. Similar momentum is emerging in eosinophilic COPD following approvals of dupilumab and mepolizumab. Implementation remains constrained by FeNO availability, payer policies, and prior authorization, often overriding clinical choice. Depemokimab introduces twice-yearly dosing but raises monitoring and coverage questions. CT-quantified mucus plug burden is gaining traction as a third predictive biomarker in asthma and a prognostic phenotype in COPD.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

From Eosinophils to Image Biomarkers: The Evolving Science of Biologic Selection in Asthma and COPD

Vinod E. Nambudiri, MD, MBA, MPH, is affiliated with Brigham and Women's Hospital and specializes in Dermatology and Internal Medicine.

What Changes Is AI Making in Dermatology? With Vinod Nambudiri, MD, MBA, MPH

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver, following the Skin of Color Society (SOCS) Scientific Symposium, Vinod Nambudiri, MD, MBA, MPH, of Brigham and Women’s Hospital, spoke in the latest episode of the 

 on the growing impact of artificial intelligence (AI) in dermatology alongside practical strategies to support clinician well-being.

Nambudiri emphasized that AI remains a topic of both enthusiasm and uncertainty within medicine, particularly as tools such as large language models and clinical workflow integrations become more widely accessible. He noted that, beyond general-use platforms, AI is increasingly being embedded into dermatology practice in ways that can meaningfully improve day-to-day efficiency. Among the most immediate applications are AI-powered scribe tools, which can assist with clinical documentation, a well-recognized contributor to physician burnout.

By reducing time spent on note-writing, these tools may allow dermatologists to redirect focus toward patient care. Similarly, Nambudiri pointed to emerging use of AI in managing patient communication, particularly through drafting responses to electronic health record messages. While not replacing clinician oversight, such tools can help streamline inbox management and reduce administrative burden, offering what he described as a “win-win” for both workflow efficiency and clinician well-being.

In addition to technological advancements, Nambudiri discussed key themes from a panel on physician wellness, underscoring the importance of individualized approaches to sustaining professional fulfillment. He highlighted the value of incorporating humor into daily practice as a means of maintaining perspective amid the inherent stressors of clinical work. Acknowledging moments of levity, he suggested, can help clinicians navigate the challenges of a demanding healthcare environment.

Nambudiri also stressed the importance of recognizing personal and professional limitations. He described the ability to acknowledge uncertainty, whether by telling a patient “I don’t know” or seeking input from colleagues, as a critical component of both effective care and personal resilience. Rather than diminishing physician confidence, he suggested that this transparency can strengthen the therapeutic relationship and support more thoughtful, collaborative decision-making.

Additional insights from the session included the role of habit formation, gratitude, and strong team dynamics in promoting well-being. Ultimately, Nambudiri framed clinician wellness as a highly individualized process, encouraging dermatologists to identify strategies that align with their own needs while continuing to adapt to an evolving clinical landscape shaped by innovations such as AI.

Editor’s note: This summary was developed with the help of AI tools.

At the 2026 AAD Annual Meeting, Nambudiri spoke on various points, including how emerging AI tools may help reduce administrative burden in dermatology.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Treatment Selection in Psoriasis

In ‘Treatment Selection in Psoriasis,’ our panelists focus on the growing body of long-term data supporting sustained disease control and remission in psoriasis, while also highlighting how these data inform real-world treatment selection. The expert faculty discuss emerging evidence demonstrating that a proportion of patients can achieve and maintain complete skin clearance over several years of continuous therapy. This concept of sustained remission is framed as a more stringent and clinically relevant outcome.

The discussion also explores how long-term durability data translate into everyday clinical treatment decisions. With an expanding number of biologic therapies available, clinicians must navigate the choices within limited patient visit times. The faculty highlights the importance of considering individual patient characteristics, such as comorbidities, body weight, presence of psoriatic arthritis, and treatment history, when selecting the most appropriate therapy.

Additionally, the panelists address the evolving expectations around treatment performance, including speed of response, depth of clearance, and durability. The ability to achieve both fast and sustained results is recognized as a key driver of patient satisfaction and quality of life. They also touch on practical considerations, such as dose adjustments and payer dynamics, which can influence treatment selection in real-world settings. The discussion underscores the shift toward personalized, data-driven decision-making in psoriasis care, where long-term outcomes and patient-specific factors guide the pursuit of sustained remission.

Our next episode, ‘Comparing Biologic Classes and Durability in Psoriasis,’ the faculty compares biologic classes in psoriasis, focusing on differences in speed of response and long-term durability. It highlights how emerging head-to-head data and within-class differences are shaping more individualized treatment decisions.

New psoriasis data show durable, rapid skin clearance with modern biologics, spotlighting bimekizumab’s four-year remission and patient-tailored selection.

Video Series

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

 has expanded the indication for teplizumab-mzwv (Tzield) to include children as young as 1 year of age with stage 2 

, allowing use to delay progression to clinical (stage 3) disease.

The decision, announced by Sanofi on April 22, 2026, extends prior approval for patients aged 8 years and older and marks the first disease-modifying therapy available for very young children at high risk of developing symptomatic T1D. The expanded indication is supported by safety and pharmacokinetic data from the phase 4 PETITE-T1D study.

"This approval opens an important new chapter in diabetes care for young children with stage 2 type 1 diabetes and their families,” said Kimber Simmons, MD, MS, associate professor of pediatrics at the Barbara Davis Center, in a press release. “This is especially important because these children are often at the highest risk of progressing quickly and without warning. Delaying the onset of stage 3 type 1 diabetes during the years when management is often most difficult because of a child’s small size and dependence on caregivers could have a truly meaningful impact for families."

FDA Expands Tzield Indication to Younger Children With Stage 2 Type 1 Diabetes

Teplizumab is a CD3-directed monoclonal antibody designed to modulate the autoimmune process underlying T1D. It was 

 to delay progression to stage 3 disease in adults and pediatric patients aged 8 years and older with stage 2 T1D.

The updated approval now includes children aged 1 year and older with stage 2 disease, defined by the presence of 2 or more T1D-associated autoantibodies and dysglycemia. This stage precedes symptomatic diabetes but reflects ongoing autoimmune-mediated beta-cell destruction.

The FDA granted the expanded indication under priority review, reflecting the unmet need for interventions that can alter disease progression in early T1D.

The expanded approval is based on data from PETITE-T1D, a phase 4, open-label, single-arm, multicenter study evaluating teplizumab in children younger than 8 years with stage 2 T1D.

The study enrolled 23 participants who received a 14-day course of intravenous teplizumab. The trial was designed primarily to assess safety and pharmacokinetics rather than efficacy outcomes.

Although limited by its small size and nonrandomized design, the study provided supportive evidence that the safety profile of teplizumab in younger children is consistent with that observed in older populations.¹

The approval reinforces a shift toward earlier intervention in T1D, focusing on modifying disease course before the onset of clinical symptoms. At the time of the April 22, 2026 announcement, teplizumab remains the only FDA-approved therapy with this disease-modifying intent in T1D.

Regulatory review is ongoing for an additional indication evaluating whether teplizumab may delay progression in patients with newly diagnosed stage 3 T1D aged 8 years and older.

Teplizumab has also received regulatory approvals in multiple regions outside the US, including the European Union, United Kingdom, and Canada, for delaying progression to stage 3 T1D in patients aged 8 years and older with stage 2 disease.

Sanofi. Press Release: Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. Sanofi.com. Published April 22, 2026. Accessed April 22, 2026. 

https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-3278650

 (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D - Nov 17, 2022. Sanofi.us. Published November 17, 2022. Accessed April 22, 2026. 

https://www.news.sanofi.us/2022-11-17-TZIELD-TM-teplizumab-mzwv-approved-by-FDA-as-the-first-and-only-treatment-indicated-to-delay-the-onset-of-Stage-3-type-1-diabetes-T1D-in-adult-and-pediatric-patients-aged-8-years-and-older-with-Stage-2-T1D

The FDA expanded teplizumab-mzwv (Tzield) to delay progression from stage 2 to stage 3 type 1 diabetes in children aged ≥1 year, extending the prior ≥8-year indication. Stage 2 disease is defined by at least two T1D-associated autoantibodies plus dysglycemia, reflecting active autoimmune beta-cell destruction before symptomatic diabetes. The priority review decision was supported by phase 4 PETITE-T1D safety and pharmacokinetic data from 23 children treated with a 14-day IV course, showing consistency with older populations.

Teplizumab is now approved to treat stage 2 type 1 diabetes in kids 1 year and older.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

FDA News

FDA Expands Teplizumab Approval to Children 1 Year & Older to Delay Type 1 Diabetes Onset

Explore how psoriasis biologics differ—TNF vs IL‑23/IL‑17—why classes matter, and what targeted therapy means for safety and results.

Understanding Biologic Therapies in Psoriasis

Learn when IV iron beats pills and when endoscopy matters in GI-related anemia—from bariatric surgery to IBD, celiac, GAVE, angiectasias.

ASH Clinical Practice Guidelines in Development and Remaining Evidence Gaps in IDA Management 

Armstrong’s interview highlights oral therapies in the psoriasis treatment space highlighted in her session at the 2026 AAD meeting.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Recent Oral Therapy Developments in Psoriasis, With April W. Armstrong, MD, MPH

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Hematology

Strategic Alliance Partnership

First-Generation Gene Editing in Sickle Cell Faces Real-World Limits Despite Breakthrough Results

Anick Bérard PhD, a researcher at CHU Sainte-Justine in Montreal, professor at the University of Montreal, and an adjunct professor Université Claude Bernard Lyon 1.

In an interview, Bérard discusses population-based data showing no increased risk of major congenital malformations with first-trimester asthma controller use.

Asthma Controllers Safe in First Trimester, With Anick Bérard, PhD

Aliza Narva, JD, BSN, MSN, director of ethics at the Hospital of the University of Pennsylvania.

In a Q&A with Dominic Sisti, Narva discusses ethics consult workflows, common conflicts, and lessons from complex ICU cases.



Clinical Ethics Consultation in Practice, With Aliza Narva, JD, MSN

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Ravulizumab reduced proteinuria by week 10 and met the primary endpoint in the phase 3 I CAN trial in IgA nephropathy.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Breaking News

Ravulizumab Reduces Proteinuria as Early as Week 10 in Phase 3 I CAN Trial for IgAN

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

There is an antifungal-resistant dermatophyte spreading globally, and experts are urging clinicians to become more aware.

When First-Line Fails: The Rising Threat of Treatment-Resistant Dermatoses

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

If approved, the novel corticosteroid therapy would be the first and only FDA-approved hydrocortisone acetate suppository.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

FDA Accepts NDA For Next-Generation Hydrocortisone Acetate in Ulcerative Colitis of the Rectum

The FDA accepted Genentech's sBLA for obinutuzumab in SLE based on positive phase 3 ALLEGORY trial results, with a decision expected by December 2026.

Latest News

Psychiatry Infrastructure Lags Psychedelic Momentum, With Gus Alva, MD

From Eosinophils to Image Biomarkers: The Evolving Science of Biologic Selection in Asthma and COPD

What Changes Is AI Making in Dermatology? With Vinod Nambudiri, MD, MBA, MPH

Treatment Selection in Psoriasis

FDA Expands Teplizumab Approval to Children 1 Year & Older to Delay Type 1 Diabetes Onset